Acquisition of Nora Pharma Inc. (Details Narrative) |
9 Months Ended | ||
|---|---|---|---|
|
Oct. 20, 2022
USD ($)
shares
|
Sep. 30, 2026 |
Oct. 20, 2022
CAD ($)
|
|
| Malek Chamoun [Member] | |||
| Business Combination [Line Items] | |||
| Earnout description | During the fiscal year ended December 31, 2023, the Company paid an earnout amount of $1,426,914 CAD (approximately $1,036,500 USD) for the fiscal year ended December 31, 2022. On April 22, 2024, the Company paid another earnout amount of $3,093,878 CAD (approximately $2,247,400 USD) for the fiscal year ended December 31, 2023. The remaining earnout amount of $479,208 CAD ($295,797 USD) was paid by the Company to Mr. Chamoun on August 10, 2026 | ||
| Nora Pharma Inc. [Member] | |||
| Business Combination [Line Items] | |||
| Purchase price | $ 18,860,637 | ||
| Paid in cash | $ 14,346,637 | ||
| Stock issued for acquisition | shares | 10 | ||
| Stock issued for acquisition, value | $ 4,514,000 | ||
| Nora Pharma Inc. [Member] | Malek Chamoun [Member] | |||
| Business Combination [Line Items] | |||
| Earnout payable | $ 3,632,000 | $ 5,000,000 |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Number of shares of stock issued during the period pursuant to acquisitions. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Value of stock issued pursuant to acquisitions during the period. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|